Literature DB >> 26810645

Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.

Shuo Zhang1, Jiazhen Chen2, Peng Cui2, Wanliang Shi1, Xiaohong Shi3, Hongxia Niu4, Denise Chan5, Wing Wai Yew5, Wenhong Zhang2, Ying Zhang6.   

Abstract

Linezolid (LZD) has become increasingly important for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its mechanisms of resistance are not well characterized. We isolated 32 mutants ofMycobacterium tuberculosiswith reduced susceptibility to LZD, which was accounted for byrrlandrplCmutations in almost equal proportions, causing lower and higher MICs, respectively. Our findings provide useful information for the rapid detection of LZD resistance for improved treatment of MDR-TB.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26810645      PMCID： PMC4808145          DOI： 10.1128/AAC.02941-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.

Authors:  Y Zhang; W-W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2015-11       Impact factor: 2.373

2.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.

Authors:  Tsi-Shu Huang; Yung-Ching Liu; Cheng-Len Sy; Yao-Shen Chen; Hui-Zin Tu; Bao-Chen Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Authors:  Patrick Beckert; Doris Hillemann; Thomas A Kohl; Jörn Kalinowski; Elvira Richter; Stefan Niemann; Silke Feuerriegel
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  Elvira Richter; Sabine Rüsch-Gerdes; Doris Hillemann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.

Authors:  Zhijian Zhang; Yu Pang; Yufeng Wang; Changting Liu; Yanlin Zhao
Journal:  Int J Antimicrob Agents       Date:  2013-12-31       Impact factor: 5.283

6.  Linezolid in the treatment of multidrug-resistant tuberculosis.

Authors:  G F Schecter; C Scott; L True; A Raftery; J Flood; S Mase
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

7.  The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Authors:  S M Swaney; H Aoki; M C Ganoza; D L Shinabarger
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

9.  Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Wanliang Shi; Wei Liu; Wenhong Zhang; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2013-06-12       Impact factor: 7.163

Review 10.  The emerging problem of linezolid-resistant Staphylococcus.

Authors:  Bing Gu; Theodoros Kelesidis; Sotirios Tsiodras; Janet Hindler; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.758
View more
  15 in total

1.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

Review 2.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

3.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors:  Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 4.  Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.

Authors:  Filia Stephanie; Mutiara Saragih; Usman Sumo Friend Tambunan
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 5.  Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.

Authors:  Guilherme Felipe Dos Santos Fernandes; Chung Man Chin; Jean Leandro Dos Santos
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-01

6.  Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.

Authors:  Jeong Seong Yang; Kyung Jong Kim; Hongjo Choi; Seung Heon Lee
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

7.  Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.

Authors:  Sean Wasserman; Gail Louw; Limpho Ramangoaela; Garrick Barber; Cindy Hayes; Shaheed Vally Omar; Gary Maartens; Clifton Barry; Taeksun Song; Graeme Meintjes
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

8.  Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.

Authors:  Guilherme Felipe Dos Santos Fernandes; Paula Carolina de Souza; Elsa Moreno-Viguri; Mery Santivañez-Veliz; Rocio Paucar; Silvia Pérez-Silanes; Konstantin Chegaev; Stefano Guglielmo; Loretta Lazzarato; Roberta Fruttero; Chung Man Chin; Patricia Bento da Silva; Marlus Chorilli; Mariana Cristina Solcia; Camila Maríngolo Ribeiro; Caio Sander Paiva Silva; Leonardo Biancolino Marino; Priscila Longhin Bosquesi; Debbie M Hunt; Luiz Pedro S de Carvalho; Carlos Alberto de Souza Costa; Sang Hyun Cho; Yuehong Wang; Scott Gary Franzblau; Fernando Rogério Pavan; Jean Leandro Dos Santos
Journal:  J Med Chem       Date:  2017-10-16       Impact factor: 7.446

Review 9.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293

10.  Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis.

Authors:  N Ismail; S V Omar; N A Ismail; R P H Peters
Journal:  Data Brief       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.